Toremifene citrate

DRUG4 trials

Sponsors

GTx, Japan Breast Cancer Research Network, Fred Hutchinson Cancer Center, Xijing Hospital

Conditions

Breast Cancer OrganoidsBreast NeoplasmsFracturesHER2/Neu NegativeInvasive Breast CarcinomaOsteoporosisPostmenopausalProstate Cancer

Phase 2

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

TerminatedNCT00437359

Japan Breast Cancer Research NetworkBreast Neoplasms

Start: 2007-05-31End: 2020-05-31Target: 240Updated: 2012-03-30

Phase 3

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

CompletedNCT00129142

GTxFractures, Osteoporosis, Prostate Cancer

Start: 2003-10-31End: 2007-11-30Target: 1200Updated: 2013-11-15

Phase 4

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

WithdrawnNCT03238703

Fred Hutchinson Cancer CenterHER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal +2

Start: 2018-09-01End: 2025-03-14Updated: 2018-12-27

Unknown Phase

Breast Cancer Treatment Based on Organ-like Culture

Xijing HospitalBreast Cancer Organoids

Start: 2019-01-02End: 2021-12-15Target: 300Updated: 2019-04-24

Related Papers

Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels to levels similar to orchiectomy: What is that value?

Journal of Clinical Oncology2014-02-01